WO2008050140A3 - Compounds for treatment of parasitic infection - Google Patents

Compounds for treatment of parasitic infection Download PDF

Info

Publication number
WO2008050140A3
WO2008050140A3 PCT/GB2007/004093 GB2007004093W WO2008050140A3 WO 2008050140 A3 WO2008050140 A3 WO 2008050140A3 GB 2007004093 W GB2007004093 W GB 2007004093W WO 2008050140 A3 WO2008050140 A3 WO 2008050140A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
parasitic infection
compounds
parasitic
infection
Prior art date
Application number
PCT/GB2007/004093
Other languages
French (fr)
Other versions
WO2008050140A2 (en
Inventor
Moses Lee
Terry Spithill
Stephanie Yanow
Lisa Purcell
Original Assignee
Spirogen Ltd
Moses Lee
Terry Spithill
Stephanie Yanow
Lisa Purcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spirogen Ltd, Moses Lee, Terry Spithill, Stephanie Yanow, Lisa Purcell filed Critical Spirogen Ltd
Publication of WO2008050140A2 publication Critical patent/WO2008050140A2/en
Publication of WO2008050140A3 publication Critical patent/WO2008050140A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound such as AS-I-145 for use in a method of treatment of a parasitic infection or for use in a method of prevention of a parasitic infection mediated by sporozoites.
PCT/GB2007/004093 2006-10-27 2007-10-26 Compounds for treatment of parasitic infection WO2008050140A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86314906P 2006-10-27 2006-10-27
US60/863,149 2006-10-27
US88717007P 2007-01-30 2007-01-30
US60/887,170 2007-01-30
US95354607P 2007-08-02 2007-08-02
US60/953,546 2007-08-02

Publications (2)

Publication Number Publication Date
WO2008050140A2 WO2008050140A2 (en) 2008-05-02
WO2008050140A3 true WO2008050140A3 (en) 2008-11-27

Family

ID=38982096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004093 WO2008050140A2 (en) 2006-10-27 2007-10-26 Compounds for treatment of parasitic infection

Country Status (1)

Country Link
WO (1) WO2008050140A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415117B2 (en) 2012-10-12 2016-08-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US12121590B2 (en) 2023-06-06 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
KR101671360B1 (en) 2010-04-15 2016-11-01 시애틀 지네틱스, 인크. Targeted pyrrolobenzodiazepine conjugates
WO2011130616A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines used to treat proliferative diseases
NL2007292C2 (en) 2011-05-27 2013-02-27 Univ Griffith Blood stage malaria vaccine.
CN103987718A (en) 2011-09-20 2014-08-13 斯皮罗根有限公司 Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
EA028457B1 (en) 2011-10-14 2017-11-30 Медимьюн Лимитед Pyrrolobenzodiazepines
EA036202B1 (en) 2011-10-14 2020-10-14 Сиэтл Дженетикс, Инк. Pyrrolobenzodiazepines and targeted conjugates
BR112014008981A2 (en) 2011-10-14 2017-05-02 Spirogen Sàrl pyrrolobenzodiazepines
EP3388435B1 (en) 2011-10-14 2023-05-03 Seagen Inc. Pyrrolobenzodiazepines and targeted conjugates
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014057072A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
EP2935268B2 (en) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105246894A (en) 2012-12-21 2016-01-13 斯皮罗根有限公司 Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2015013739A1 (en) * 2013-07-29 2015-02-05 Griffith University Attenuated babesia vaccine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3047683C (en) 2017-02-08 2020-03-10 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (en) 2017-04-18 2022-10-10 Medimmune Limited Pyrrolobenzodiazepine conjugates
LT3668874T (en) 2017-08-18 2022-03-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AR116908A1 (en) * 2018-12-18 2021-06-23 Elanco Tiergesundheit Ag BICYCLIC DERIVATIVES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030894A2 (en) * 2000-09-19 2002-04-18 Taiho Pharmaceutical Co., Ltd. Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030894A2 (en) * 2000-09-19 2002-04-18 Taiho Pharmaceutical Co., Ltd. Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ATSUSHI SATO ET AL: "A Novel Class of in Vivo Active Anticancer Agents: Achiral seco-Amino- and seco-Hydroxycyclopropylbenz[e]indolone (seco-CBI) Analogues of the Duocarmycins and CC-1065", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 48, no. 11, 5 May 2005 (2005-05-05), pages 3903 - 3918, XP007905657, ISSN: 0022-2623, [retrieved on 20050505] *
ORJIH A U ET AL: "Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei.", TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE 1982, vol. 76, no. 1, 1982, pages 57 - 61, XP002496709, ISSN: 0035-9203 *
PURCELL L A ET AL: "Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice", INFECTION AND IMMUNITY 200803 US, vol. 76, no. 3, March 2008 (2008-03-01), pages 1193 - 1199, XP002496710, ISSN: 0019-9567 *
WATERS A P ET AL: "MALARIA VACCINES: BACK TO THE FUTURE?", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 307, no. 5709, 28 January 2005 (2005-01-28), pages 528 - 530, XP009074371, ISSN: 0036-8075 *
YANOW ET AL: "The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 148, no. 1, 1 July 2006 (2006-07-01), pages 52 - 59, XP005477957, ISSN: 0166-6851 *
YANOW S K ET AL: "Genomics-based drug design targets the AT-rich malaria parasite: Implications for antiparasite chemotherapy", PHARMACOGENOMICS, ASHLEY PUBLICATIONS, GB, vol. 8, no. 9, 1 January 2007 (2007-01-01), pages 1267 - 1272, XP008096540, ISSN: 1462-2416 *
YANOW STEPHANIE K ET AL: "Potent antimalarial and transmission-blocking activities of centanamycin, a novel DNA-binding agent", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, vol. 197, no. 4, 15 February 2008 (2008-02-15), pages 527 - 534, XP008096537, ISSN: 0022-1899 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415117B2 (en) 2012-10-12 2016-08-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US12121590B2 (en) 2023-06-06 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
WO2008050140A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008050140A3 (en) Compounds for treatment of parasitic infection
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2008051416A3 (en) Compounds that inhibit the activity of hsp90 for treating infections
AU2005235116A1 (en) Combinations for treating HIV infection
EP1756106A4 (en) Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007011760A3 (en) Inhibitors of mitotic kinesin
WO2008115281A3 (en) Compounds for treating viral infections
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
WO2008133734A3 (en) Method and compositions for treating hiv infections
WO2009098458A3 (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension
WO2008002855A8 (en) Methods for the treatment of wounds
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
EP1827475A4 (en) Method for treatment of hiv infection
WO2007115287A3 (en) Combination of organic compounds
MY144154A (en) Method of combating infection
WO2008087416A3 (en) Antimicrobial composition and a method of controlling contamination and infection using said composition
WO2011021230A3 (en) Complexes for treatment and/or prophylaxis of parasitic infections
WO2008064004A3 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2007106400A3 (en) Pyridine-containing macroheterocylic compounds as kinase inhibitors
AU2006901583A0 (en) Method for prophylaxis or treatment
AU2006901413A0 (en) Method of treatment or prophylaxis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824337

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07824337

Country of ref document: EP

Kind code of ref document: A2